RxDoctor Payments Data

Kelly Slavik-Bosworth

Family · Lorain, OHNPI 1366039935

Payments from drug & device makers

$792in general payments, 2019–2025

Across 18 payments — averaging $44.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$373
  • Johnson & Johnson$126
  • Madrigal Pharmaceuticals$117
  • Boehringer Ingelheim$30
  • Novo Nordisk$28
  • Sanofi Pasteur Inc.$24
  • plus $94 from 6 others

What the payments were for

  • Food & beverage$792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$792 in reported general payments places this provider in the 65th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$15,077
Medicare patients
107
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid12$113,612
LinzessLinaclotide66$43,308
Sucralfate44$9,452
Mesalamine ErMesalamine16$8,219
Mesalamine16$3,440
Dexlansoprazole DrDexlansoprazole12$3,155
Omeprazole198$2,286
CholestyramineCholestyramine (With Sugar)16$1,809
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg77$1,672
Esomeprazole Magnesium66$1,276
Pantoprazole Sodium199$1,252
Famotidine132$1,148
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates15$925
Dicyclomine Hcl69$849
LoperamideLoperamide Hcl16$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$373$43,30866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,812 family providers in Ohio.

Other family in Lorain

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →